Blackhill Capital Inc. Trims Holdings in Eli Lilly and Company $LLY

Key Points

• Blackhill Capital Inc. reduced its stake in Eli Lilly and Company by 0.5%, owning 146,358 shares valued at approximately $120.88 million, making it the fund's second-largest holding.
• Major institutional investors have increased their stakes significantly, with PNC Financial Services Group raising its holdings by 97.5% to 101.3 million shares, and GAMMA Investing LLC increasing theirs by a staggering 103,831.6%.
• Eli Lilly reported a strong quarterly performance with earnings per share of $6.31, surpassing estimates, and set a FY 2025 guidance of 21.750-23.000 EPS, while also announcing a quarterly dividend of $1.50 per share.

Blackhill Capital Inc. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 0.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 146,358 shares of the company's stock after selling 710 shares during the quarter. Eli Lilly and Company makes up approximately 7.0% of Blackhill Capital Inc.'s holdings, making the stock its 2nd biggest holding. Blackhill Capital Inc.'s holdings in Eli Lilly and Company were worth $120,879,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC lifted its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the period. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in Eli Lilly and Company during the 1st quarter worth approximately $40,000. Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company during the 4th quarter worth approximately $43,000. Finally, O Brien Wealth Partners LLC increased its stake in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after purchasing an additional 12 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks bought 1,632 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the transaction, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gabrielle Sulzberger bought 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded up $0.9090 during mid-day trading on Friday, reaching $710.7290. The company had a trading volume of 3,217,264 shares, compared to its average volume of 6,973,298. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a one year low of $623.78 and a one year high of $972.48. The firm has a market cap of $672.68 billion, a price-to-earnings ratio of 46.45, a PEG ratio of 0.99 and a beta of 0.44. The business's 50-day simple moving average is $754.70 and its 200 day simple moving average is $790.90.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the business earned $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 39.22%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LLY shares. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Finally, DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.